Recombinant Human CDK4/CCND3, GST-tagged, Active

• Cat.No.: CDK4/CCND3-275H
• Product Overview: Recombinant human full-length CDK4 and CyclinD3 were co-expressed by baculovirus inSf9cells using an N-terminal GST tag on both proteins. MW=58 kDa and CyclinD3 ~58 kDa.

Specification

• Cat. No.: CDK4/CCND3-275H
• Description: CDK4 is a member of the cyclin-dependent protein kinase family and is involved in the control of cell proliferation during the G1 phase of cell cycle. CDK4 forms a complex with the D-type cyclins and is inhibited by p16 (cyclin-dependent kinase inhibitor-2). CDK4 can mediate phosphorylation of the C-terminal region of RB protein leading to an active transcriptional repression of E2F complex. CDC37 and HSP90 can preferentially associate with the fraction of CDK4 not bound to D-type cyclins. SMAD3 is a major physiologic substrate of the G1 cyclin-dependent kinases CDK4 and CDK2.
• Source: Sf9 insect cells using baculovirus.
• Sequence: Full-length.
• Applications: Kinase Assay, Western Blot.
• Storage And Stability: Store product at –70°C. For optimal storage, aliquot target into smaller quantities after centrifugation and store at recommended temperature. For most favorable performance, avoid repeated handling and multiple freeze/thaw cycles.

Gene Information

• Gene Name: CDK4 cyclin-dependent kinase 4 [ Homo sapiens ],CCND3 cyclin D3 [ Homo sapiens ]
• Synonyms: CDK4; cyclin-dependent kinase 4; CMM3; PSK-J3; MGC14458; cell division kinase 4; melanoma cutaneous malignant, 3; EC 2.7.11.22; CCND3;cyclin D3; G1/S-specific cyclin-D3
• Gene ID: 1019,896
• mRNA Refseq: NM_000075,NM_001136017
• Protein Refseq: NP_000066,NP_001129489
• UniProt ID: P11802, P30281
• Chromosome Location: 12q14, 6p21
• MIM: 123829,123834
• Pathway: Bladder cancer; Cell cycle; Chronic myeloid leukemia; Glioma; Melanoma; Non-small cell lung cancer; Pancreatic cancer; Pathways in cancer; Small cell lung cancer; T cell receptor signaling pathway; Tight junction; p53 signaling pathway; Cell Cycle, Mitotic; Jak-STAT signaling pathway;Wnt signaling pathway
• Function: cyclin-dependent protein kinase activity; ATP binding; nucleotide binding; transferase activity;protein kinase binding; protein binding

Reviews

02/18/2023

Whether it's troubleshooting experimental issues, providing guidance on experimental design, or answering any inquiries related to the CDK4 protein, the manufacturer is committed to helping researchers overcome challenges and achieve their scientific goals.

02/16/2020

They actively seek feedback and incorporate it into their product development process, continuously improving the quality and performance of the CDK4 protein.

05/29/2018

The manufacturer also values customer satisfaction and strives to maintain a strong relationship with researchers.

Q&As

Are there any potential challenges in targeting CDK4 for cancer therapy?

Resistance to CDK4 inhibitors and the need for patient stratification are some of the challenges in using CDK4 as a therapeutic target.

Can CDK4 be targeted for cancer therapy?

Yes, CDK4 is a target for cancer therapy, and drugs that inhibit CDK4 have been developed for the treatment of specific cancers.

How is CDK4 clinically relevant?

CDK4 is clinically relevant because it plays a crucial role in the development and progression of various cancers.

Which cancers are commonly associated with CDK4 overactivity?

CDK4 overactivity is commonly associated with breast cancer, melanoma, and liposarcoma.

How does CDK4 relate to cell senescence?

CDK4 can promote cell senescence, a state of irreversible growth arrest, which has implications in cancer therapy.